UA138906U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, the patient's serum determines the polymorphism of methylenetetrahydrofolate reductase genes (MTHFR C677T), nitric oxide synthase (eNOS T786C), endothelin, folic acid, pyridinoline, C-reactive protein (SRP) I, intern. With a homozygous carrier of 677-TT, 786-CC and endothelin levels> 10 ng / ml, folic acid <6 ng / ml, pyridinoline> 8 ng / ml, PSA> 6 mg / l, IL-6> 10 ng / l predict development of osteoarthritis.

Description

The proposed useful model, a method of predicting the development of osteoarthritis, belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of an opportunity to predict the dynamics of the process in the early subclinical stages, to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

Сб677Т), nitric oxide synthase (6ЭМО5 1786С), the content of endothelin, folic acid, pyridinoline,

C-reactive protein (CRP), interleukin 6 (IL-6). With homozygous carrier 677-1, 786-

SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline "8 ng/ml, SRP 26 mg/l,

IL-6 210 ng/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of endothelin, folic acid, pyridinoline, SRP, IL-6 is determined by the immunoenzymatic method. With homozygous carrier 677-177, 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline "8 ng/ml, SRP "b mg/l, IL-6 "10 ng/l predict the development osteoarthritis

A specific example of using the method.

Patient 0., 56 years old, was hospitalized in the clinic due to pain syndrome in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and eMmo5 17860 genes was determined in blood serum. The content of endothelin, folic acid, pyridinoline, SRP, IL-6 was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, levels of endothelin - 22 ng/ml, folic acid - 3.5 ng/ml, pyridinoline - 15 ng/ml, SRP - 16 mg/l, IL-6-25 ng/ l. The development of osteoarthritis was diagnosed.

After 11 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphism of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (EMO5 1786С), the content of endothelin, folic acid, pyridinoline, C-reactive protein (SRP), interleukin 6 (IL-b) and with homozygous carrier 677-TT, 786-SS and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline 28 ng/ml, SRP 26 mg/l, IL-6 "10 ng/l predict the development of osteoarthritis .